People may eat more calories after stopping weight loss drugs, according to Deutsche Bank survey
Publishing timestamp: 2024-01-09 09:38:43
Summary
A survey by Deutsche Bank found that calorie consumption declines when patients take GLP-1 medication like Novo Nordisk's Ozempic or Wegovy. However, once the medication is stopped, the number of calories consumed by patients will rise again, and in some cases, it will be even higher than before treatment. The survey also found that the impact of anti-obesity medications on food and beverage stocks needs to be assessed in the context of all weight loss programs. Compliance with anti-obesity medications is low, similar to other chronic disease medications. Deutsche Bank expects interest in weight loss programs to be peaking, which could be a good time for investors to hold food and beverage stocks.
Sentiment: MIXED
Tickers: ULVR-GB, UL, NSRGF, MDLZ, NOVO.B-DK, NES.N-CH, LLY, KHC, CPUH,
Keywords: breaking news: investing, unilever plc, eli lilly and co, nestle sa, mondelez international inc, kraft heinz co, investment strategy, novo nordisk a/s, compute health acquisition corp, business news, stock markets,